Conferences - Results from #80

Viewing 81-100 of 11531 articles

SNMMI 2024: Primary Lesion Ga-68 PSMA-11 Total Lesion Activity Is a Highly Sensitive Predictor with High Negative Predictive Value of Advanced Stage in Initial Staging of Patients with Moderate to High-Risk Prostate Cancer

SNMMI 2024: 68Ga-PSMA-11 PET/CT for Baseline Staging of High-Risk Prostate Cancer: Associations Between Clinical Risk Factors, Metastases and Imaging Parameters

SNMMI 2024: 18F-PSMA-1007 PET /CT in Evaluation of Atypical Patterns of Spread in ISUP Grade Group 5 Prostate Cancer and Correlation with NKX3.1 Immunohistochemistry

SNMMI 2024: Percutaneous Trans-Gluteal Ga-68 PSMA PET/CT Guided Prostate Biopsy in Men with Equivocal Multiparametric MRI Findings (PIRADS≤3 Prostatic Lesion)

SNMMI 2024: PSMA RLT- To Combine or Not to Combine

SNMMI 2024: Update from the PSMA-dRT Trial: A Randomized Phase III Trial of PSMA-PET/CT Prior to Definitive Radiation Therapy for Unfavorable Intermediate-risk or High-risk Prostate Cancer

SNMMI 2024: 18F-rhPSMA-7 and 18F-flotufolastat PET-guided Salvage Radiotherapy in Recurrent Prostate Cancer

SNMMI 2024: The Tumor Sink Effect on PSMA-PET/CT in Metastatic Prostate Cancer and its Implications for PSMA-RLT: Insight from the 3TMPO Study

AMA 2024: 2024 American Medical Association Annual House of Delegates Meeting Primer

ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?

ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options?

ASCO 2024: Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer

ASCO 2024: Artificial Intelligence and Deep Learning in Prostate Cancer Pathology

ASCO 2024: Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer

ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

ASCO 2024: FGFR3 Alterations in Patients Who Develop Locally Advanced or Metastatic Urothelial Cancer, and Their Association with Tumor Subtype and Clinical Outcomes in Patients Treated with Erdafitinib Versus Pembrolizumab

ASCO 2024: Cost-Effectiveness Analysis of Contemporary First-Line Agents in Locally Advanced/metastatic Urothelial Carcinoma

ASCO 2024: Considerations in Treating and Palliating Variant Genitourinary Cancers Where No Standard of Care Exists

ASCO 2024: Age and Other Criteria Influencing Non-Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries

ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

1
2
3
4
5
6
7
8
9
10